Market Size (2018)
$898.87M
Vertical: HealthcareBase Year: 2018
Market Size (2018)
$898.87M
Projected (2024)
$1.29B
CAGR (2016–2024)
5.9%
Key Players
6+
A stroke occurs when the blood flow to an area of the brain is cut off. This leads to improper supply of oxygen to the cells, which then begin to die. As per the National Stroke Association survey, 2016, around 800,000 people suffer from recurrent stroke every year. It is the fifth leading cause of death in the US. Growing geriatric population, rise in incidences of stroke, and increasing disease awareness drive the growth of the global stroke post processing software market. However, stringent regulatory policies may hamper the growth of the market.
The global stroke post processing software market is expected to register a CAGR of 6.48% during the forecast period of 2019 to 2024. In 2018, the market was led by Europe with 37.9% share, followed by the Americas and Asia-Pacific with shares of 35.6% and 16.4%, respectively.
The global stroke post processing software market has been segmented based on installation, modality, type, end user, and region.
Based on installation, the desktop segment accounted for the largest market share of 48.5% in 2018, with a market value of USD 436.18 million, which is projected to register a CAGR of 6.72% during the forecast period.
On the basis of modality, the CT scan segment accounted for the largest market share of 63.6% in 2018, with a market value of USD 571.43 million, which is projected to register a CAGR of 6.81% during the forecast period.
Based on type, the ischemic stroke segment accounted for the largest market share of 67.5% in 2018, with a market value of USD 606.73 million, which is projected to register a CAGR of 6.57% during the forecast period.
On the basis of end user, the hospitals & clinics segment accounted for the largest market share of 53.4% in 2018, with a market value of USD 479.89 million, which is projected to register a CAGR of 6.72% during the forecast period.
The Stroke Post Processing Software Market market is projected to grow at a CAGR of 5.9% from 2016 to 2024.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansStroke Post Processing Software Market
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Mn)
A stroke can be defined as the lack of blood flow to brain tissues, and this can occur in any vascular structure within the brain. Moreover, increasing awareness regarding the benefit of stroke post processing software in individuals as well as healthcare professionals would create more demand for these products. Hence it helps boost the growth of the global stroke post processing software market.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThis report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
2018
Historical Period
2016 – 2017
Forecast Period
2019 – 2024
Primary Interviews
150+
Historical data (2016–2018) and forecast period (2018–2024)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThe global stroke post processing software market is expected to be a very lucrative, attractive, and profitable market, both for existing as well as new entrants. At the same time, intense rivalry among existing competitors has been observed. Our analysis revealed that the key market players had adopted different strategies to increase their business and position in the global stroke post processing software market. In recent years, strategies such as product launches, acquisitions, and approvals, were adopted by key players to reduce competition and generate market growth. The major players in the global stroke post processing software market are Brainomix, Viz.ai, Inc., iSchemaView, Inc., and others.
Companies are entering into collaborations with big players in the healthcare industry to neutralize growing competition from customers, competitors, and to tackle the changing market dynamics.
A few key players are operating in this market globally. Mostly, these players exist in the Americas and Europe. The market players in these regions, provide a wide range of products for various applications. Owing to the limited players in the market, the market shares are marginally differentiated. Some of the major players in the global stroke post processing software market include Brainomix, Viz.ai, Inc., iSchemaView, Inc., and others. These are top players in the global stroke post processing software market, contributing almost 81.5% of the total global stroke post processing market.
Bargaining Power of Suppliers
Bargaining power of suppliers in the global stroke post processing software market is low to medium. The suppliers in the global stroke post processing software market are also the manufacturers of this software. Currently, a low number of suppliers are present in the market as the market is new, and the regulatory scenario is stringent. Switching cost of the suppliers is medium because suppliers tend to enter into long-term associations, partnerships, and deals with companies that buy the stroke post processing software.
Bargaining Power of Buyers
The bargaining power of buyers is medium to high in the global stroke post processing software market due to the presence of multiple buyers of stroke post processing software. The buyers of stroke post processing software primarily include diagnostic centers and hospitals. Since very few suppliers are present in the market, buyers can exert moderate pressure on manufacturers. The market is captured by a limited number of players, which indicates oligopoly in the market, which leads to a few options with regard to products offering. Thus, the bargaining power of buyers tends to be medium to high in this market.
The Threat of New Entrants
The threat of new entrants is medium to high in the global stroke post processing software market. Any company trying to enter the stroke post processing software market is required to accept and maintain regulatory standards, and the product must be approved by regulatory authorities. This market has a lot of opportunities for many major medical device companies to enter the market.
Threat of Substitutes
There is no direct substitute for stroke post processing software in the market. Moreover, there are very few market players in the market. So, even though on the internal level, customers can switch from one company’s product to others, the low to medium degree of switching cost may minimize the threat of substitutes. Hence, the threat of substitutes in the global stroke post processing software market is low.
Intensity of Rivalry
The degree of competition in the global stroke post processing software market is medium. Not many manufacturers are present in the market, and it is shared by a few players. The market share of players is fixed, which indicates moderate rivalry. Players are engaged in developing processes to reduce their manufacturing costs to overcome the existing competition. Moreover, players also develop advanced techniques to differentiate their products from their rivals.
Market estimates by geography (2024)
InsightAmericas leads with $476.89M by 2024, while North America is projected to grow fastest at a 6.9% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2016 | 2018 | 2024 | CAGR | SHARE |
|---|---|---|---|---|---|
| Middle East and Africa | $82.16M | $100.48M | $131.77M | 6.1% | 7% |
| North America | $243.08M | $306.57M | $414.64M | 6.9% | 23% |
| Americas | $288.64M | $358.26M | $476.89M | 6.5% | 27% |
| Asia Pacific | $132.27M | $165.77M | $222.79M | 6.7% | 13% |
| Europe | $316.92M | $370.28M | $462.79M | 4.8% | 26% |
| South America | $45.56M | $51.69M | $62.24M | 4.0% | 4% |
| Total | $1.11B | $1.35B | $1.77B | 5.9% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$1.29B
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Ischemic Stroke | $1.19B | 6.9% | 67% |
| Hemorrhagic Stroke | $416.14M | 7.0% | 23% |
| Others | $165.46M | 5.6% | 9% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.

Analytical insights on Stroke Post Processing Software Market covering market dynamics, competitive landscape, and strategic outlook.
The Stroke Post Processing Software Market market is projected to reach $1.29B by 2024, growing at 5.9% CAGR. The Ischemic Stroke segment holds the largest share.
Stroke can be defined as lack of blood flow to brain tissue and this can occur in any vascular structure within the brain. Stoke symptoms vary based on individual and region of the brain that has been deprived of blood flow. As per survey carried out by American Stroke Association in 2016, 1,40,000 death can be seen due to stoke in US every year. Hence there is rising demand for stroke post processing software. Software currently available in the market, designed for perfusion of CT studies, are generally divided into two groups such as convolutional and deconvolutional, depending on the use of varied mathematical algorithms. Therefore, even though parameters are given the same name in various software packages, there may be significant disparities between them if they are calculated using different algorithms. The global stroke post processing software market is expected to grow due to increasing burden of Ischemic strokes and rising demand for health care services.
The stroke post processing software market has significant growth potential. Key players in this segment are focusing on partnerships and collaborations to increase their customer base and to enhance geographical presence across the globe. For instance, in January 2019, iSchemaView and NeuroLogica, a subsidiary of Samsung Electronics Co., Ltd. and leader in medical imaging technology, collaborated to integrate iSchemaView’s RAPID cerebrovascular imaging platform with NeuroLogica’s portable CereTom computed tomography (CT) scanners for use in Mobile Stroke Units (MSUs) and Intensive Care Units (ICUs) across the globe. Moreover, in April 2018, Brainomix received USD 9.8 million funding in collaboration with Boehringer Ingelheim in order to bring its software to the market. These collaborations have given iSchemaView and Brainomix to expand globally. As adoption of stroke post processing software in the healthcare industry is increasing, big market players are focusing on collaborating with small companies to expand in the market and for the development of new products in this field. This focus is anticipated to drive the market growth.
Developing economies pose an opportunity for various markets as they have undeveloped research and development sectors owing to which they are unable to address upcoming health challenges. Despite huge demand, the African region is dependent on imported medicines and other health technologies. Although there is a high requirement for treatment, poor economic conditions lead to the slow growth of the healthcare industry within the African region. As per the statistics of the American Stroke Association Report 2016, around 800,000 people in the United States have a stroke and these patients were treated with Stroke Post Processing Software. This huge population affected with the chronic diseases in developing countries serves as a strong opportunity for key players operating in the stroke post processing software market.
Regulatory compliance is the primary hurdle challenging the stroke post processing software market at every point. The growing prevalence of chronic diseases, as well as increased awareness regarding the benefit of stroke post processing software in individuals as well as healthcare professionals, have contributed to rapid growth in the demand for stroke post processing software for treatment of various disorders. Besides, Indian manufacturers are investing more in stroke post processing software transplant to comply with the US FDA regulations for obtaining contracts from the US-based companies. Although these regulations are serving to improve and maintain the quality of these devices, they are also curbing the growth of the devices manufacturing market especially in developing regions of Asia-Pacific.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 102 companies operating in the Stroke Post Processing Software Market market, including revenue, employee count, and market positioning where available.
Showing 102 of 102 companies
Brainomix
Company Headquarters: Oxford, UK Founded: 2010 Workforce: ~50 Company Working: Brainomix is a start-up by the University of Oxford. It develops medical imaging software that can automatically interpret brain CT scans of patients who have suffered a stroke or are undergoing diagnosis for it. It develops imaging biomarkers for neurological and cerebrovascular disorders. The software supports physicians in identifying the patients that can benefit from life-saving stroke treatment. The company has a team of expert clinicians, stroke neurologists, scientists, business professionals, and engineers who give necessary insights and experience to cater to the demands of its customers. The company offers e-Aspects which is a medical imaging software that automates the Alberta Stroke Program Early CT Score system. This helps create brain images from acute ischemic stroke patients to identify and quantify signs of early stroke damage and assist the physician's decision of how to treat the disease. The company’s software evaluates stroke damage on brain CT scans, addresses the lack of brain CT scan interpretation availability, and guides assessment of eligibility of stroke patients for life-saving treatment.
General Electric Company
Novavax, Inc.
Company Headquarters: Maryland, US Founded: 1987 Workforce: ~2,500 Company Working: Novavax, Inc. is a biotechnology company that commercializes and develops vaccines to prevent a wide range of infectious diseases. It designs recombinant nanoparticle vaccine technology that produces a strong immune response against a variety of pathogens. It is partnered with leading biopharma organizations, government agencies, research institutions, and foundations, namely the Coalition for Epidemic Preparedness Innovations (US), the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (US), the Serum Institute of India Pvt. Ltd. (India), SK Bioscience (South Korea), CPL Biological (India), and Takeda Pharmaceuticals (US). It has seven research and manufacturing facilities. It has presence in regions namely North America, Europe, and the Middle East and Africa
Cleveland Biolabs, Inc
Company Headquarters: New York, US Founded: 2003 Workforce: ~150 Company Working: Cleveland Biolabs, Inc. is an innovative biopharmaceutical company developing products to address immune system diseases and serious medical needs. It is specialized in offering products such as radiation injury products, immune-oncology, and orphan drugs. It has nine product candidates in its pipeline that have been developing directly through itself or its wholly owned companies, namely Incuron, LLC (US) and Panacela Labs, Inc. (US). It has a proprietary platform, namely the Advanced Immunomodulating Multi-Receptor System (AIMS) platform, which is designed to restore immune homeostasis. Moreover, it has collaboration with government agencies which supports the advanced development and procurement of new medical countermeasures including drugs, vaccines, diagnostics, and medical supplies in order to protect public health from chemical, biological, radiological, and nuclear threats.
SIGA Technologies
Company Headquarters: New York, US Founded: 1995 Workforce: ~50 Company Working: SIGA Technologies (SIGA) is a pharmaceutical business at the commercialization stage that develops and offers antiviral treatments for smallpox, monkeypox, cowpox, and vaccinia complications. The company has an established research and development collaboration with US federal entities. It provides countermeasures to the Strategic National Stockpile (SNS) and the Department of Defense (DoD). TPOXX ("oral TPOXX," also known as "tecovirimat" in certain overseas markets) is the Company's lead product, which it distributes to the US government and international governments (including government-affiliated entities). In addition, the Company sells TPOXX intravenous formulation ("IV TPOXX") to the US Government
Altimmune
Company Headquarters: Maryland, US Founded: 1997 Workforce: ~50 Company Working: Altimmune is a clinical-stage biopharmaceutical business focusing on treating obesity and liver illnesses. The business is working on HepTcell, an immunotherapeutic drug aimed at providing a functional cure for chronic hepatitis B. The company was formed through the merger of PharmAthene, Inc. ("PharmAthene") with the company formerly known as Altimmune
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence